Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery


A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining


Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of kidney cancer. Giving celecoxib together with recombinant interferon alpha-2b may kill more tumor cells and be an effective treatment for metastatic kidney cancer.


This phase II trial is studying how well giving celecoxib together with recombinant interferon alfa-2b works in treating patients with metastatic kidney cancer who have undergone surgery.

Study Status: Completed


Condition Intervention Phase
Renal Cell Cancer
Stage IV Renal Cell Cancer
Drug: celecoxib
Biological: recombinant interferon alfa-2b
Other: polymerase chain reaction
Other: laboratory biomarker analysis
Other: reverse transcriptase-polymerase chain reaction
Other: immunologic technique
Other: immunohistochemistry staining method
Other: flow cytometry
Phase 2

Verified by Case Comprehensive Cancer Center August, 2012

Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center identifier: NCT01158534

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States

Brian Rini., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site